Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - midazolam, quantity: 50 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; sodium chloride - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - English - Department of Health (Therapeutic Goods Administration)

velvet pure australia pty ltd - deer velvet antler powder -

Australia - English - Department of Health (Therapeutic Goods Administration)

velvet pure australia pty ltd - deer velvet antler powder -

Australia - English - Department of Health (Therapeutic Goods Administration)

velvet pure australia pty ltd - deer velvet antler powder -

Australia - English - Department of Health (Therapeutic Goods Administration)

velvet pure australia pty ltd - deer velvet antler powder -

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - dexamethasone sodium phosphate - solution for injection/infusion - 4 milligram(s)/millilitre - glucocorticoids; dexamethasone - glucocorticoids - it e can be used for all forms of general and local glucocorticoid injection therapy and all acute conditions in which intravenous glucocorticoids may be life-saving.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 3.3mg/1ml solution for injection ampoules (hameln pharma ltd - dexamethasone sodium phosphate - solution for injection - 3.3mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.